Prevalence of Post COVID-19 Condition among healthcare workers: self-reported online survey in four African countries

- 3 Hager Elnadi,¹ Ahmad I. Al-Mustapha, ^{1,2,3*} Ismail A. Odetokun, ⁴ AbdulAzeez Adeyemi Anjorin,⁵
- 4 Rasha Mosbah, ^{6,7} Folorunso O. Fasina, ^{8,9} Youssef Razouqi, ¹⁰ Kwame Sherrif Awiagah, ¹¹ Jean
- 5 Baptiste Nyandwi, ¹² Zuhal E. Mhgoob, ¹³ George Gachara, ¹⁴ Mohamed Farah Yusuf Mohamud ^{15,16}
- 6 Bamu F. Damaris¹⁷ Aala MohamedOsman Maisara¹⁸ Mona Radwan¹⁹
- ¹ Infectious Disease and One Health, Faculty of Pharmaceutical Sciences, Universite de Tours,
 France.
- ² Department of Veterinary Services, Kwara State Ministry of Agriculture and Rural Development,
 Ilorin, Nigeria.
- ³ Department of Veterinary Public Health and Preventive Medicine, Faculty of Veterinary Medicine,
 University of Helsinki, Finland.
- ⁴ Department of Veterinary Public Health & Preventive Medicine, Faculty of Veterinary Medicine,
- 14 University of Ilorin, Nigeria
- ⁵ Department of Microbiology (Virology Research), Lagos State University, Nigeria
- ⁶ Faculty of Oral and Dental Medicine, Ahram Canadian University, Egypt
- ⁷ Infection Control Unit, Zagazig University, Zagazig, Egypt.
- 18 ⁸ Emergency Centre for Transboundary Animal Diseases (ECTAD), Food and Agricultural
- 19 Organization of the United Nations (FAO), Tanzania.
- ⁹ Department of Veterinary Tropical Disease, University of Pretoria, Pretoria, South Africa
- ¹⁰ Biological Engineering Laboratory, Sultan Moulay Slimane University Beni Mellal, Morocco
- 22 ¹¹ Training and Research Unit, Korle Bu Teaching Hospital, Ghana
- ¹² Department of Pharmacy, University of Rwanda, Rwanda.
- 24 ¹³ Department of Public Health & Infection Control, Aljawda Hospital & El Nileen University
- 25 Community Development College, Khartoum, Sudan
- ¹⁴ Department of Medical Laboratory Science, Kenyatta University, Nairobi, Kenya.
- ¹⁵ Department of Emergency Medicine at Mogadishu Somali Turkish Training and Research Hospital,
 Mogadishu, Somalia
- 29 ¹⁶ Department of Research at Jazeera University, Mogadishu, Somalia
- 30 ¹⁷ Hannover Medical School, Hannover, Germany.
- 31 ¹⁸ Department of Nephrology and Hemodialysis, International University of Africa, Khartoum, Sudan
- ¹⁹ Department of Public Health, Faculty of Medicine, Zagazig University, Egypt
- 33
- 34 Corresponding author:
- 35 Ahmad I. Al-Mustapha (<u>ahmad.al-mustapha@helsinki.fi</u>, <u>ai.almustapha42@gmail.com</u>)
- 36 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

37 Abstract

The impact of Post COVID-19 Condition is ongoing despite the WHO declaration that the 38 pandemic has ended. In this study, we explore the prevalence of PCC among healthcare 39 40 workers (HCWs) in four African Countries and its influence on their professional performance. This study was conducted as an online cross-sectional survey of healthcare workers from four 41 African countries (Cameroon, Egypt, Nigeria, and Somalia) between the 20th of December 42 2021 to 12th of January 2022. We determined the prevalence of PCC based on the WHO case 43 definition and assessed variables associated with a higher prevalence of PCC in these countries 44 45 using univariable and multivariable logistic regression analyses. A total of 706 HCWs from four African countries were included in this survey. Most of the HCWs were aged between 18-46 34 years (75.8%, n=535). Our findings showed that 19.5% (n=138) of the HCWs had tested 47 48 positive for SARS-CoV-2. However, 8.4% (n=59) were symptomatic for COVID-19 but tested negative or were never tested. Two-thirds of the HCWs (66.4%, n=469) have received a 49 50 COVID-19 vaccine and 80.6% (n=378) of those vaccinated had been fully vaccinated. The 51 self-reported awareness rate of PCC among the HCWs was 16.1% (n=114/706) whereas the awareness rate of PCC among COVID-19-positive HCWs was 55.3 % (n=109/197). The 52 prevalence of PCC among HCWs was 58.8% (n=116). These changes include the self-reported 53 54 symptoms of PCC which included headache (58.4%, n=115), fatigue (58.8%, n=116), and muscle pain (39.6%, n=78). Similarly, 30% (n=59) and 20.8% (n=41) of the HCWs reported 55 the loss of smell and loss of taste long after their COVID-19 infection, respectively. Some 56 57 HCWs (42%, n=83) believed that their work performance has been affected by their ongoing 58 symptoms of PCC. There was no significant difference in the prevalence of PCC among the 59 vaccinated and unvaccinated HCWs (p > 0.05). Of the socio-demographic variables, age (older HCWs between 45-54 years; OR:1.7; 95% CI: 1.06, 10.59; p = 0.001) and location (Egypt; 60 OR:14.57; 95% CI: 2.62, 26.76; p = 0.001) were more likely to have experienced PCC than 61 other age groups and countries respectively. The study revealed low prevalence of PCC among 62 the surveyed HCC. In addition, it observed the need for adequate medical and psychological 63 64 support to HCWs with PCC, improve their COVID-19 vaccination uptake, and conduct mass 65 advocacy campaigns on PCC.


66

~ 7	Keywords: PCC,	COUD 10	1 COVID	A.C	HOW.
67	Kevwords, but	(1) (1) - 19	$1000 - (1) \times 11$	ATRICA	HUWS
	1	com n n		, <i>i</i> inica,	110 11 5

68

69

- 70
- /0
- 71
- 72 Graphical abstract



73

COVID-19 positivity rate (n =197), vaccination rate (n =706), PCC awareness rate (n = 114), and prevalence of PCC (n = 116) in HCWs across four African countries.

- 76 77 78 79
 - 80

81 **1. Introduction**

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the 2019 coronavirus disease (COVID-19) pandemic. SARS-CoV-2 mainly affects the respiratory system and the disease, COVID-19 has various clinical presentations, which vary from mild to severe, especially among elderly and immunocompromised patients [1].

By 7th of June 2023, more than 767 million confirmed COVID-19 cases have been reported,

87 which has resulted in 6,941,095 million deaths globally. In Africa, COVID-19 reported cases

were around 9,534 million with 175,373 COVID-19-associated deaths (case fatality rate of 2%) 88 [2]. To curb the spread of the SARS-CoV-2 virus, governments across the world initially 89 instituted non-pharmaceutical interventions (the use of face masks, hand hygiene, physical 90 distancing, and related measures) and later pharmaceutical interventions (mainly vaccines). 91 The accelerating and efficient development, production, distribution, and acceptance of the 92 COVID-19 vaccines have helped curb the disease spread, reduce hospitalization rates, and 93 94 reduced the severity of the disease, particularly among infected patients [3]. The tremendous effect of the COVID-19 vaccines in reducing the disease transmission and the return of routine 95 daily life worldwide, led to WHO's announcement on 5th of May 2023, that COVID-19 96 pandemic is no longer a public health emergency [4]. 97

98 After a COVID-19 infection, most of the ill patients return to their normal health status within 99 days to a few weeks. However, some patients continue to suffer from ongoing, recurrent, or 100 long-term health issues post-infection [5,6]. For instance, some patients were reported to 101 experience a wide range of symptoms such as headache, fatigue, change in taste or smell, 102 irregular menstruation, and mood changes among others, for months, post-infection [7-8].

To gain a significant understanding of these long-term COVID-19 adverse events, the World 103 Health Organization (WHO) published a temporary clinical case definition for such cases, 104 [5,9]. In October 2021, WHO announced that symptoms/signs which were previously termed 105 106 long-term COVID-19, chronic COVID-19, or Post COVID-19 syndrome, are now identified as Post COVID-19 Condition (PCC) [5]. Despite the identification of these COVID-19 107 sequelae as PCC by WHO, they lack clear classifications and several things remain unclear [5]. 108 109 For instance, the impact of vaccinations on the incidence of PCC requires further studies. Al-Aly et al.,[10] reported that COVID-19 vaccines reduced the likelihood of PCC in people who 110 had been infected by only about 15% whereas Antonelli et al., reported that two doses of the 111 COVID-19 vaccines halved the risk of PCC [11]. 112

For instance, PCC had been reported in COVID-19 survivors regardless of their COVID-19 113 severity (mild or severe), presentation (acute, sub-acute, or chronic), and whether the patient 114 was hospitalized or not [8,9]. In addition, the PCC is similar to the post-SARS (severe acute 115 respiratory syndrome coronavirus 1) and the Middle East Respiratory Syndrome Coronavirus 116 (MERS CoV) syndromes (with symptoms such as fatigue, myalgia, psychiatric presentation, 117 as well as pulmonary and bone complications) that have affected SARS, MERS CoV survivors 118 119 for up to 4-15 years post-infection [12-18]. Given the insufficient information about its effects on individuals' health during the illness, or 120 long after recovery, PCC may have a negative impact not only on the patient's health but also 121 on their personal and professional life. Thus, the USA considered PCC a disability under the 122 Americans with Disabilities Act (ADA) since July 2021 [4]. However, there is a paucity of 123 reliable data about the COVID-19 pandemic and PCC in Africa. Therefore, this study assessed 124 the prevalence of PCC and its association with the work performance of healthcare workers 125 (HCWs) in four African countries. 126

127

128

129 **2.** Materials and Methods

130 **2.1 Ethical clearance**

The ethical clearance for this study was obtained from the Kwara State Ministry of Health, Ilorin, Nigeria with reference number MOH/KS/EHC/777/502 as well as the ethical review board of the Faculty of Human Medicine of the University of Zagazig, Egypt (Reference number: ZU-IRB #9241/2-1-2022). We obtained written informed consent from each respondent after brief information on the purpose of the study was provided to them. To participate in the study, a respondent must tick the consent box in the mobile application

(ODK). Participation in this survey was voluntary and without prejudice, as participants couldwithdraw from the survey at any time.

139 **2.2 Study Participants and survey methodology**

This study presented the preliminary findings from a larger study that was conducted as a cross-140 sectional online survey of HCWs across Africa between the 20th of December 2021 to 12th of 141 January 2022. HCWs included anyone that provides health services and advice based on formal 142 training and experience. Hence, they included physicians, nurses, veterinarians, etc. The 143 144 questionnaire was designed using Google Forms (Google incorporated) and administered via online social media platforms such as WhatsApp, Facebook, and E-mails. Our inclusion criteria 145 were age (18 years and above), location (Africa), and occupation (healthcare worker). Other 146 African countries (n=12) with less than 100 respondents were excluded from this preliminary 147 analysis. 148

149 2.3 Study variables

This study evaluated four self-reported variables among HCWs in each country. These were: 150 1). COVID-19 positivity rate, 2). COVID-19 full vaccination rate, 3). awareness of PCC, and 151 4). prevalence of PCC among HCWs. The COVID-19 positivity rate among HCWs was 152 essential to understand the prevalence of COVID-19 in HCWs and evaluating the occupational 153 154 exposure of HCWs in these countries. The second study variable evaluated the vaccination coverage of HCWs in these countries. Although HCWs were designated as priority recipients 155 for the COVID-19 vaccination, acceptance of the vaccine is voluntary. Hence, our interest in 156 the vaccination status of HCWs. The third variable evaluated the awareness of PCC (especially 157 its symptoms and clinical presentation). This is crucial to the diagnosis of PCC among patients. 158 The final study variable evaluated the prevalence of PCC among HCWs. Based on the WHO 159 160 case definition, a respondent was classified as having PCC if the individual had a history of

probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset of COVID-19,
with symptoms lasting for at least 2 months that could not be explained by an alternative
diagnosis [5]. So, only respondents that fit the four criteria of the WHO case definition of PCC
were regarded as having PCC.

165 **2.4 Questionnaire design**

The awareness of PCC among HCWs was assessed using a semi-structured pre-validated 166 questionnaire. The survey instrument was further validated by three independent academic 167 168 examiners to ascertain the content and face validity of the adapted questionnaire as well as observe for any technical glitches. In addition, the reliability of the survey instrument was 169 assessed using the Cronbach Alpha test (with a score of 0.72) based on 11 purposefully selected 170 171 questions. Finally, the questionnaire was pre-tested among 10 HCWs from each of the four 172 countries before the deployment of the final version for data collection. The results of the pretest were not included in the final analysis. 173

The questionnaire was designed in three of the most common languages in Africa (Arabic, English, and French). The back-to-back translation was validated by two linguists to ensure that the intended meaning of each question was not lost. In each of the translations, the questionnaire was divided into 4 sections: a). Socio-demographic information on HCWs b). history and course of COVID-19 infection c). Awareness of PCC among HCWs d). Impact on work performance.

180 **2.5 Data analysis**

The data obtained from this survey were analyzed using Statistical Package for Social Sciences (SPSS) version 26 (IBM Corp., Armonk, N.Y., USA). We conducted descriptive statistics and summarized the information as frequency and percentages. Chi-square analysis was used to test for association between the four key study variables (COVID-19 positivity rate, COVID- 185 19 full vaccination rate, awareness of PCC, and the prevalence of PCC) in the four countries. 186 Finally, the significant variables (p-value < 0.05) were entered into a logistic regression model 187 (univariable and multivariable) to determine the association between the socio-demographic 188 variables (age, gender, occupation, and their country of origin) and the outcome variable 189 (prevalence of PCC in HCWs). The odds ratios generated from the multivariable logistic 190 regression analysis were used for all the inferences in this study.

191 **3. Results**

192 **3.1 Healthcare worker demographics**

A total of 713 HCWs filled out the survey instrument out of which 99% (n=706) gave consent and responded to the questionnaire (Table 1). The distribution from the four African countries was Egypt (n = 281), Nigeria (n = 210), Somalia (n = 111), and Cameroon (n = 104). Most of the HCWs were aged between 18-34 years (75.8%, n=535). Of the respondents, nurses represented 36.3% (n=256) and more female respondents were recruited (55.8%, n=394).

Variables	Number (%)
Nationality	
Cameroon	104 (14.7)
Egypt	281 (39.8)
Nigeria	210 (29.8)
Somalia	111 (15.7)
Occupation	
Dentist	38 (5.4)
Nurse	256 (36.3)
Physician	143 (20.3)
Pharmacist	42 (6.1)
Laboratory technician	74 (6.7)
Veterinarian	79 (11.2)
Others*	74 (6.7)
Age	
18 - 24	283 (40.1)
25-34	252 (35.7)

198	Table 1. Demographics of HCWs recruited int	o this study (n=706).
-----	---	-----------------------

35-44	125 (17.7)
45-54	36 (5.1)
>55	10 (1.4)
Gender	
Female	394 (55.8)
Male	301 (42.6)
Prefer not to say	11 (1.6)
Do you have a known chronic disease?	
No	646 (91.5)
Yes	60 (8.5)

Others*: scientific officers, health information technologists, and clinical medical students
who work or study in a health facility.

201

3.2 COVID-19 infection among healthcare workers

203 Of the 706 HCWs included in this survey, 19.5% (n=138/706) tested positive for SARS-CoV-2 by real-time polymerase chain reaction (RT-PCR), rapid diagnostic test (RDT), or reverse 204 transcription loop-mediated isothermal amplification (RT-LAMP). In addition, 8.4% 205 (n=59/706) of the HCWs were probable COVID-19 cases. During their COVID-19 infection, 206 22.3% of them had moderate to severe symptoms and were admitted to a health facility (Table 207 2). Our findings showed that two-thirds of the HCWs (66.4%, n=469) in these countries have 208 received a COVID-19 vaccine and 80.6% (n=378) of those vaccinated had received their 209 second dose (fully vaccinated). A quarter of the HCWs (27.5%, n=38) were tested less than a 210 211 month before this survey.

Variables	Number (%)	
1. Have you ever been diag	nosed with COVID-19? ($n = 706$)	
No	568 (80.5)	
Yes	138 (19.5)	
Have you noticed the symptoms of COVID-19 which were not confirmed (probable cases)? $(n = 568)$		
No	509 (72)	
Yes	59 (8.4)	
3. When was your last COVID-19 test conducted? $(n = 127)$		
< 1 month ago	38 (27.5)	
2-3 months	13 (9.4)	
3-6 Months	20 (14.5)	

Table 2. History of COVID-19 infection among healthcare workers recruited into this study.

6-12 months	30 (21.7)			
12-18 months	24 (17.4)			
>18 months	2 (2.2)			
4. Were you admitted to a health facility during your COVID-19 infection? $(n = 197)$				
No	153 (77.7)			
Yes 44 (22.3)				
5. Have you received any of the approved COVID-19 vaccines? $(n = 706)$				
No 237 (33.6)				
Yes	469 (66.4)			
6. Are you fully vaccinated against COVID-19? ($n = 469$)				
No 91 (19.4)				
Yes	378 (80.6)			

213

The awareness rate of PCC among the general HCWs was 16.1% (n=114/706) whereas the 214 215 awareness rate of PCC among COVID-19-positive HCWs was 55.3 % (n=109/197). Based on 216 the WHO case definition, more than half of the COVID-19-positive HCWs (58.8%, n=116/197) were deemed to have PCC and one-third (35.5%, n=70/197) of them noticed 217 changes in their health status due to the PCC. These changes include the symptoms of PCC 218 which included headache (58.4%, n=115), fatigue (58.8%, n=116), and muscle pain (39.6%, 219 n=78). Similarly, 30% (n=59) of the HCWs reported the loss of smell after their COVID-19 220 221 infection and 20.8% (n=41) of the HCWs experienced the loss of taste long after their COVID-19 infection. Other less frequent COVID-19 symptoms experienced by HCWs in the 4 African 222 countries included rash, pins and needles, and memory problems (Figure 1). Half of the HCWs 223 224 (53.3%, n=105) reported that their symptoms of PCC were mostly mild, and only 6.9% of them (n=14) were admitted due to their PCC or its symptoms (Table 3). 225

Table 3. Structure of PCC among HCWs in four African countries (n=197).


Variable	Number (%)				
1. Are you aware of the term "post-COVID-19 condition"? $(n = 706)$					
No	592 (83.9)				
Yes	114 (16.1)				
2. Have you noticed any changes in your health status after the COVID-19 infection? $(n = 197)$					
No	127 (64.5)				
Yes	70 (35.5)				
3. How would you describe the severity of your PCC? $(n = 192)$					
Mild/moderate	181 (94.3)				
Severe	10 (5.2)				

10

Very severe	1 (0.5)			
4. Have you been admitted t	o a health facility due to the PCC? $(n = 197)$			
No	183 (93.1)			
Yes	14 (6.9)			
5. Have you received any treatment for your PCC? $(n = 197)$				
No	125 (63.4)			
Yes	72 (36.6)			



229



230

Table 4. Perception of COVID-19 infection and PCC on work performance among HCWs (n=197).

Variable	Number (%)
1. How would you describe your work environ	nment stress level after experiencing the PCC?

<sup>Figure 1. Frequency of PCC symptoms among COVID-19-positive healthcare workers from
four African countries, 2022 (n = 197/706).</sup>

²³³ **3.3 Work Performance**

Only 29.7% (n=58) of the HCWs who experienced COVID-19 and PCC described their work

environment as more stressful. In addition, 42% (n=83) of them believed that their performance

at work has been affected by their PCC. Approximately half of the HCWs (49.3%, n=97) got

tired faster than usual whereas 16.2% of them (n=32) got more forgetful after their COVID-19

²³⁸ infection (Table 4).

Less stressful	87 (44)			
Same environmental stress level	52 (26.3)			
More stressful	58 (29.7)			
2. Has your performance at work been affec				
No	114 (58)			
Yes	83 (42)			
3. On a scale of 5, how severely has the CC HCW?	OVID-19 pandemic affected your work as an			
1	76 (38.8)			
2	43 (22)			
3	47 (24)			
4	23 (11.7)			
5	7 (3.5)			
4. How has the PCC affected your work	performance?			
I get tired faster now	97 (49.3)			
I feel less motivated	44 (22.3)			
I feel more stressed	49 (24.9)			
I have less tolerability	39 (19.8)			
I get more forgetful	32 (16.2)			
5. Have you received proper support from your workplace?				
No	63 (43.5)			
Yes	82 (56.5)			

241

242 **3.4 Post-Covid Condition among African healthcare workers**

243 Across the four countries, there were statistically significant differences in the positivity rate of COVID-19 infection among HCWs, their vaccination rates, their awareness of PCC, and the 244 prevalence of PCC among HCWs (Table S2). HCWs in Somalia tested more positive for 245 COVID-19 than HCWs in other countries (p < 0.05). However, more HCWs in Nigeria (73.8%, 246 n=155) had received full COVID-19 vaccines than in the three other countries (p < 0.05). The 247 248 highest awareness rate of PCC was in Somalia HCWs where 25.2% of them knew about PCC (Table S2). The prevalence of PCC among COVID-19-positive HCWs was 58.8% (n=116). 249 However, there were no significant differences in the prevalence of PCC among the vaccinated 250 251 and un-vaccinated HCWs (p > 0.05).

252 Of the sociodemographic variables, only nationality significantly impacted the prevalence of

253 PCC among HCWs in Africa. Hence, HCWs in Egypt were more likely (OR:14.57; 95% CI:

254 2.62, 60.76; p = 0.001) to have experienced PCC than HCWs in the three other countries (Table

- 5). This is further evident in the fact that 90.7% (n=49) of the 54 Egyptian HCWs who tested
- 256 positive for the SARS-COV-2, experienced PCC.

Table 5. Logistic regression analysis of demographic variables that affected the prevalence of PCC among HCWs.

Outcome	Variable	Baseline category		OR (95% CI)	p-value	OR (95% CI)	p-value
variable							
			Univariat	ble analysis		Multivariable a	nalysis
	Age (years)	18-24	25-34	3.50 (2.17, 5.65)	0.027	0.47 (0.08, 2.71)	< 0.001
			35-44	2.27 (1.26, 4.09)		0.86 (0.11, 6.52)	
			45-54	4.00 (1.78, 9.00)		1.70 (1.01, 10.59)	
			>55	6.1 (1.61, 22.81)		0.34 (0.01, 6.01)	
	Admission due to	No	Yes	1.14 (0.53, 2.47)	0.738	-	-
Prevalence	COVID-19						
of PCC	Gender	Male	Female	0.89 (0.42, 1.86)	0.322	-	_
among	Nationality	Cameroon	Egypt	10.14 (3.00, 34.27)	< 0.01	14.57 (2.62, 26.76)	0.002
HCWs			Nigeria	3.28 (0.92,11.78)		3.18 (0.51, 19.78)	
			Somalia	0.78 (0.47, 1.31)		0.82 (0.47, 1.48)	
	Occupation	Physician	Nurse	2.47 (0.87,6.95)	0.051	-	-
			Pharmacist	3.57 (0.94, 13.44)			
			Technician	1.91 (0.50, 7.23)			
			Veterinarian	0.35 (0.06, 1.83)			
			Others	0.59 (0.14, 2.56)			

4. Discussion

Globally, HCWs play vital roles as frontline response personnel during the COVID-19 pandemic, especially in emergency responses, public education, and case management. This however exposes them to a higher risk of COVID-19. One of the problems associated with the COVID-19 infection is the persistence of symptoms which is generally referred to as "long COVID" or "PCC" [5]. Here, we present the first PCC survey that targeted HCWs across four African countries (Cameroon, Egypt, Nigeria, and Somalia). The COVID-19 pandemic affected the healthcare system in most African countries.

Our findings showed that 19.5% of HCWs who participated in this study had confirmed the COVID-19 diagnostic test, while 8.4% had COVID-19 symptoms and signs but without a confirmatory test. Therefore, the prevalence of SARS-CoV-2 infection among the HCWs was 270 27.9% (n=197) in the aforementioned four African countries. The highest COVID-19 positivity 271 rate was among Somali HCWs (52.1%).

272 Our results showed a higher prevalence rate than recorded by studies such as those of Galanis et al., [17] and Gómez-Ochoa et al., [18], where they observed the seroprevalence of SARS-273 CoV-2 in African HCWs were around 8.2% and 7-11% in 2021 respectively. However, another 274 study in the same year observed a wider range of prevalence (0 - 45.1%) of COVID-19 among 275 HCWs in 11 African countries [19]. A recent meta-analysis reported that 10.1% of COVID-19 276 patients were healthcare workers (HCWs) [20]. The variability in the prevalence rate of 277 COVID-19 among HCWs could be attributed to the sensitivities and specificities of the 278 diagnostic tests used (self-reported vs serosurveillance), the study design, the wave of the 279 pandemic in each country, the period the samples were taken, and the country-specific 280 contextual differences. For instance, Muller et al [19] solely relied on rapid antibody diagnostic 281 tests and their results differed between African countries, with 45.1% of seroprevalence in 282 Nigeria and 1.3% seropositive prevalence in Egypt by the end of 2021. 283

Our findings showed that among the 197 HCWs who suffered from COVID-19, 58.8% of them 284 experienced PCC based on the clinical symptoms and the WHO clinical case definition. This 285 PCC prevalence rate is in line with the reports of Osikomaiya et al. [21] who reported a 286 prevalence of 40.9% for PCC among the general populace in Lagos, Nigeria in 2020. In the 287 same vein, a systematic review of 57 studies with more than 250 000 participants by Groff et 288 al. [22], reported a PCC prevalence of 54% among recovered COVID-19 patients in 2021. 289 290 Also, Taquet et al. [23] reported that the prevalence of PCC in the USA was 57% during the first 6 months after a positive COVID-19 test in the year 2021. 291

292 In addition, Hyassat D, et al., [24] reported that 59.3% of the healthcare providers in Jordan reported more than one persisting COVID-19 symptom, and among them 97.5%, 62.6% and 293 40.9% reported more than one COVID-19 symptom at 1–3, 3–6 and 6–12 months, respectively, 294 after the acute phase of the infection. This finding is in consonant with our findings. However, 295 Menges et al. [25] reported a much lower PCC prevalence of 26% within 6 to 8 months in 296 COVID-19-positive patients. The slightly higher prevalence of PCC in older health 297 professionals (45-54 years old) than in other age groups could be attributed to the fact that older 298 persons were usually more symptomatic than others [26]. 299

Like other studies across the globe, the most reported symptoms of PCC in this study were 300 fatigue, headache, malaise, headache, myalgia, cough, and loss of smell among other 301 302 symptoms. These symptoms have been the most common among patients diagnosed with PCC across the globe. For instance, Montenegro et al. [27] and Iwu et al. [28] reported that fatigue, 303 anosmia, headache, and dyspnoea have been the most complaints among PCC patients. In 304 305 addition, Osikomaiya et al. [23] observed that 12.8% of patients with PCC in Nigeria had persistent fatigability and another 12.8% had a headache after their discharge from the hospital. 306 307 In the same vein, fatigue was the most reported symptom among Jordanian HCWs [24]. These results opined that most PCC manifestations were ongoing COVID-19 symptoms. 308

309 Our findings showed that a large proportion of the HCWs who participated in this study had no prior knowledge about PCC as only 16.6% of them were aware of PCC. For instance, Somali 310 HCWs had the highest awareness rate (25.2%) than the other three countries whilst HCWs 311 from Cameroon had the least awareness rate of PCC as only 4.8% (n=5/104) of them were 312 aware of PCC or its symptoms. The differences in the awareness rate of PCC could be due to 313 the differences in the health systems of each country, the HCW training schedule of each 314 315 country, and the occupation of the HCWs. However, the PCC awareness rate was high among COVID-19-positive HCWs as 55.3% of them were aware of PCC. 316

317 The COVID-19 vaccination rate was different in the four countries. Study participants from Cameroon had the lowest vaccination rate as only 17.3% of them were vaccinated. These low 318 vaccination rates could be because Cameroon has the lowest national COVID-19 vaccination 319 320 rates of the four countries (Table S1). Although our findings showed that HCWs from Nigeria had the highest vaccination rate, Egypt has the highest national COVID-19 vaccination rate 321 with over 71.8 million vaccinations and 29.3% of its populace fully vaccinated. These results 322 were supported by a previous study in 34 African countries which showed that only 63% of 323 their study participants were willing to accept the COVID-19 vaccine [31]. 324

More longitudinal research are needed to evaluate the impact of vaccinations on the incidence of PCC. Our data showed that the vaccination status had no impact on the prevalence of PCC as there was no significant difference (p > 0.05) in the fully vaccinated, partially vaccinated, and un-vaccinated HCWs. This is contrary to the findings of several studies which reported that COVID-19 vaccines reduced the likelihood of PCC in COVID-19 patients [32]. In the same vein, the category of the HCW (dentist, nurses, physicians, laboratory technicians, veterinarians, and others) was not associated with the prevalence of PCC in the four countries.

Besides the clinical manifestations of COVID-19, several studies have reported the 332 psychological burden of the current pandemic on HCWs irrespective of their SARS-CoV-2 333 infection status [33-38]. While HCWs know that their profession poses a high infection risk, 334 most of them were afraid to transmit the disease to their families [39]. Furthermore, other 335 studies have observed anxiety, stress, exhaustion, and depression, with increasing rates of 336 burnout among HCWs in Africa especially due to the insufficiency of personal protective 337 338 equipment and the limited number of standardized care facilities in most African countries [39-339 41].

Similar to the findings of these studies, our findings showed that psychological symptoms were 340 experienced by HCWs in the four African countries included in this study. For instance, 12.2%, 341 8.6%, and 6.1% of the HCWs had anxiety issues, mood changes, and depression respectively. 342 This psychological burden could affect the perceived stress level in HCWs. Previously, Salazar 343 et al. [42], Schwartz et. al. [43], and Chew et. al. [44] reported that the stress level at health 344 345 facilities during the pandemic was considered more apparent than pre-pandemic era, with rising levels of burnout syndrome. Conversely, the majority of the HCWs felt the work environment 346 have been either less stressful (44%) or no change in the work stress level (26.3%) during the 347 pandemic compared to the pre-pandemic era, and only 29.7% of the HCWs felt higher stress 348 level after the pandemic at their workplaces. 349

This general perception among the general HCWs was different from the PCC-affected HCWs, as 42% of the latter felt that because of their PCC, their work performance has been negatively affected. For instance, 49.3% of them got easily fatigued, while others were more stressed (24.9%), and lost their enthusiasm (22.3%). In an international study involving 56 countries, Davis et al. [45] reported that 45.2% of their study participants (n=3762) required a reduced workload due to ongoing symptoms of PCC. In addition, Twycross, A. [46] opined that the

current support scheme for healthcare professionals with PCC in the UK requires immediatereview.

358 Despite the several challenges of each country's healthcare system, HCWs in this study opined that their respective work institutions provided their affected professionals with appropriate 359 work support when they got back to work as reported by 56.5% of our HCWs that had PCC. 360 361 Recently, several studies have discussed the importance of modifying the health services settings in Africa to deliver better care for COVID-19 patients and especially for healthcare 362 workers in African countries [39, 47-53]. Interestingly, several African counties are making 363 remarkable strides to handle PCC in Africa [21]. These strides started with the recognition of 364 PCC, its burdens, as well as its management and control. In addition, Egypt recently established 365 the first clinic dedicated to PCC patients' care and treatment [54]. 366

367 This study has several limitations. Firstly, the sample size is small and the findings should not be generalized for each country. In addition, online, self-reported surveys could be biased and 368 369 usually skewed toward the younger, urban population with access to the internet. In addition, since the prevalence of PCC was based on self-reports, there was a high likelihood of 370 misclassification, misunderstanding of some questions, and over-estimation of the prevalence 371 of PCC, especially in the probable COVID-19 cases. Despite the limitations of our survey 372 373 methodology (which makes it impossible to generalize for the HCWs in each country), we 374 believe that this study will provide baseline information on PCC among HCWs in Africa.

5. Conclusion

This study presented the COVID-19 positivity rate, vaccination rate, awareness of PCC, and prevalence of PCC among HCWs in four African countries. Generally, HCWs were among the frontline response team during the COVID-19 pandemic. Therefore, it is essential to protect HCWs with a focus on improved mental health and psychological well-being and the

development of national programmes for the occupational health and safety of HCWs [55]. The COVID-19 positivity rate was high in Nigeria and Somalia. Hence, infection, prevention, and control measures as well as regular training should be instituted for HCWs in these countries. The very low COVID vaccination rate in Cameroon is worrying and the relevant health authorities in Cameroon must improve vaccination uptake, especially among HCWs. Similarly, the awareness of PCC was lowest among HCWs from Cameroon. So, mass advocacy campaigns on PCC and its varying implications should be provided for the general public in Cameroon with an emphasis on HCWs. Finally, HCWs from Egypt had the highest prevalence of PCC. Hence, adequate medical and psychological support should be provided.

402 **Declarations**

- Ethics approval and consent to participate
- 404 The ethical approval for this study was obtained from the ethical review board (ERB)
- 405 of the Kwara State Ministry of Health, Ilorin, Nigeria (reference number
- 406 MOH/KS/EHC/777/502) as well as the ERB of the Faculty of Human Medicine of the
- 407 University of Zagazig, Egypt (Reference number: ZU-IRB #9241/2-1-2022). This
- 408 study was conducted in accordance with the World Medical Association's Declaration
- 409 of Helsinki and written informed consent was obtained from each respondent.
- Consent for publication
- 411 Not Applicable
- 412 Availability of data
- 413 The datasets used and/or analyzed during the current study are available from the
- 414 corresponding author upon reasonable request.
- Competing interests
- 416 The authors declare that they have no competing interests.
- Funding
- 418 No funding was received for this study.
- Authors' contributions
- 420 HE, AIA, IAO, AAA, RM, BFD, MR, and MFYM collected data from these
- 421 countries. HE and AIA did the statistical analysis and wrote the draft manuscript.
- 422 All authors read and approved the final version of the manuscript.
- Acknowledgements
- 424 We acknowledge Dr Abubakar Musa Imam for reviewing the manuscript.
- 425
- 426

427 Table S1. COVID-19 vaccination status in the four African countries as of 6th June.

Country	Population	Total doses given	Fully vaccinated
Cameroon	26.6 million	3.66 million	3.11 million
Egypt	102 million	56.91 million	42.34 million
Nigeria	206 million	112.5 million	69.79
Somalia	15.9 million	8.37 million	7.04 million

428

- 429 Table S2. Association between the nationality of HCWs and their COVID-19 positivity,
- 430 vaccination rate, and awareness of PCC.

Egypt	Nigeria	Cameroon	Somalia	χ^2	p-value
(n=281)	(n=210)	(n=104)	(n=111)		
54 (19.2)	70 (33.3)	15 (14.4)	58 (52.3)	13.1	0.001
137 (48.8)	155 (73.8)	18 (17.3)	68 (61.3)	9.3	0.025
42 (14.9)	39 (18.6)	5 (4.8)	28 (25.2)	5.3	0.002
49 (17.4)	39 (18.6)	12 (11.5)	16 (14.4)	21.2	0.001
	(n=281) 54 (19.2) 137 (48.8) 42 (14.9)	(n=281) (n=210) 54 (19.2) 70 (33.3) 137 (48.8) 155 (73.8) 42 (14.9) 39 (18.6)	$\begin{array}{c cccc} (n=281) & (n=210) & (n=104) \\ \hline 54 & (19.2) & 70 & (33.3) & 15 & (14.4) \\ \hline 137 & (48.8) & 155 & (73.8) & 18 & (17.3) \\ \hline 42 & (14.9) & 39 & (18.6) & 5 & (4.8) \\ \hline \end{array}$	(n=281) $(n=210)$ $(n=104)$ $(n=111)$ $54 (19.2)$ $70 (33.3)$ $15 (14.4)$ $58 (52.3)$ $137 (48.8)$ $155 (73.8)$ $18 (17.3)$ $68 (61.3)$ $42 (14.9)$ $39 (18.6)$ $5 (4.8)$ $28 (25.2)$	(n=281) $(n=210)$ $(n=104)$ $(n=111)$ $54 (19.2)$ $70 (33.3)$ $15 (14.4)$ $58 (52.3)$ 13.1 $137 (48.8)$ $155 (73.8)$ $18 (17.3)$ $68 (61.3)$ 9.3 $42 (14.9)$ $39 (18.6)$ $5 (4.8)$ $28 (25.2)$ 5.3

431 χ – Chi-square

432

433 **References**

434 435	1.	Desai AD, Lavelle M, Boursiquot BC, Wan EY. Long-term complications of COVID-19. Am J Physiol Cell Physiol. 2022 Jan 1;322(1):C1-C11. doi: 10.1152/ajpcell.00375.2021.
436 437 438	2.	WHO Coronavirus (COVID-19) Dashboard. WHO Coronavirus (COVID-19) Dashboard with Vaccination Data. Available online: https://covid19.who.int/ (accessed on 8 March 2022).
439 440	3.	Eroglu B, Nuwarda RF, Ramzan I, Kayser V. A Narrative Review of COVID-19 Vaccines. Vaccines (Basel). 2021;10(1):62. Published 2021 Dec 31. doi:10.3390/vaccines10010062
441 442 443	4.	WHO (2023). <i>Coronavirus disease (covid-19) pandemic, World Health Organization.</i> Available at: https://www.who.int/europe/emergencies/situations/covid-19 (Accessed: 15 June 2023).
444 445 446	5.	CDC. National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases, https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html. Accessed on 22 February 2022
447	6.	WHO. A Clinical Case Definition of Post COVID-19 Condition by a Delphi Consensus, 6

WHO. A Clinical Case Definition of Post COVID-19 Condition by a Delphi Consensus, 6
 October 2021. Available online: <u>https://www.who.int/publications/i/item/WHO-2019-</u>

- 449 <u>nCoV-Post_COVID-19_conditi</u>on-Clinical_case_definition-2021.1 (accessed on 8
 450 December 2021).
- 451 7. Pavli A, Theodoridou M, Maltezou HC. Post-COVID Syndrome: Incidence, Clinical
 452 Spectrum, and Challenges for Primary Healthcare Professionals. Arch Med Res.
 453 2021;52(6):575-581. doi:10.1016/j.arcmed.2021.03.010
- 454 8. Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk
 455 factors, and treatments. Infect Dis (Lond). 2021 Oct;53(10):737-754. doi:
 456 10.1080/23744235.2021.1924397.
- 457 9. Lechner-Scott J, Levy M, Hawkes C, Yeh A, Giovannoni G. Long COVID or post
 458 COVID-19 syndrome. Mult Scler Relat Disord. 2021 Oct;55:103268. doi:
 459 10.1016/j.msard.2021.103268.
- 460 10. Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection.
 461 Nature Medicine. 2022;28(7):1461-1467.
- 462 11. Antonelli M, Penfold RS, Merino J, Sudre CH, Molteni E, Berry S, Canas LS, Graham
 463 MS, Klaser K, Modat M, Murray B. Risk factors and disease profile of post-vaccination
 464 SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective,
 465 community-based, nested, case-control study. The Lancet Infectious Diseases. 2022 Jan
 466 1;22(1):43-55.
- 467 12. Zhao FC, Guo KJ, Li ZR.. Osteonecrosis of the femoral head in SARS patients: seven
 468 years later. Eur J Orthop Surg Traumatol. 2013;23(6):671–677. [PubMed] [Google
 469 Scholar]
- 13. Das KM, Lee EY, Singh R, et al. Follow-up chest radiographic findings in patients with
 MERS-CoV after recovery. Indian J Radiol Imaging. 2017;27(3):342–349. [PMC free
 article] [PubMed] [Google Scholar]
- 473 14. Lee SH, Shin H-S, Park HY, et al. . Depression as a Mediator of Chronic Fatigue and Post474 Traumatic Stress Symptoms in Middle East Respiratory Syndrome Survivors. Psychiatry
 475 Investig. 2019;16(1):59–64. [PMC free article] [PubMed] [Google Scholar]
- 15. Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P, Zandi MS, Lewis
 G, David AS. Psychiatric and neuropsychiatric presentations associated with severe
 coronavirus infections: a systematic review and meta-analysis with comparison to the
 COVID-19 pandemic. Lancet Psychiatry. 2020 Jul;7(7):611-627. doi: 10.1016/S22150366(20)30203-0. Epub 2020 May 18. PMID: 32437679; PMCID: PMC7234781.
- 16. Zhang P, Li J, Liu H, et al. . Long-term bone and lung consequences associated with
 hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a
 prospective cohort study. Bone Res. 2020;8(1):8. [PMC free article] [PubMed] [Google
 Scholar]

- 485 17. Galanis P, Vraka I, Fragkou D, Bilali A, Kaitelidou D. Seroprevalence of SARS-CoV-2
 486 antibodies and associated factors in healthcare workers: a systematic review and meta487 analysis. J Hosp Infect. 2021;108:120-134. doi:10.1016/j.jhin.2020.11.008
- 488 18. Gómez-Ochoa SA, Franco OH, Rojas LZ, Raguindin PF, Roa-Díaz ZM, Wyssmann BM,
 489 Guevara SLR, Echeverría LE, Glisic M, Muka T. COVID-19 in Health-Care Workers: A
 490 Living Systematic Review and Meta-Analysis of Prevalence, Risk Factors, Clinical
 491 Characteristics, and Outcomes. Am J Epidemiol. 2021 Jan 4;190(1):161-175. doi:
 492 10.1093/aje/kwaa191.
- 493 19. Müller SA, Wood RR, Hanefeld J, El-Bcheraoui C. Seroprevalence and Risk Factors of
 494 COVID-19 in Healthcare Workers From Eleven African Countries: A Scoping Review
 495 and Appraisal of Existing Evidence. Health Policy Plan. 2021 Nov 2:czab133. doi:
 496 10.1093/heapol/czab133. Epub ahead of print. PMID: 34726740; PMCID: PMC8689910.
- 20. Sahu A.K., Amrithanand V.T., Mathew R., Aggarwal P., Nayer J., Bhoi S. COVID-19 in
 health care workers a systematic review and meta-analysis. Am J Emerg Med.
 2020;38:1727–1731.
- Sikomaiya B, Erinoso O, Wright KO, et al. 'Long COVID': persistent COVID-19
 symptoms in survivors managed in Lagos State, Nigeria. BMC Infect Dis. 2021;21(1):304.
 Published 2021 Mar 25. doi:10.1186/s12879-020-05716-x
- 503 22. Groff D., Sun A., Ssentongo A.E., Ba D.M., Parsons N., Poudel G.R., Lekoubou A., Oh
 504 J.S., Ericson J.E., Ssentongo P., et al. Short-Term and Long-Term Rates of Postacute
 505 Sequelae of SARS-CoV-2 Infection: A Systematic Review. [(accessed on 8 December
 506 2021)];JAMA Netw. Open. 2021 4:e2128568. doi:
 507 10.1001/jamanetworkopen.2021.28568.
- Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021;18(9):e1003773. Published 2021 Sep 28. doi:10.1371/journal.pmed.1003773
- 512 24. Hyassat D, El-Khateeb M, Dahbour A, Shunnaq S, Naji D, Bani Ata E. et al. Post513 COVID-19 syndrome among healthcare workers in Jordan. East Mediterr Health J. 2023
 514 Apr 27;29(4):247-253. doi: 10.26719/emhj.23.029.
- 515 25. Menges D, Ballouz T, Anagnostopoulos A, Aschmann HE, Domenghino A, Fehr JS,
 516 Puhan MA. Burden of post-COVID-19 syndrome and implications for healthcare service
 517 planning: A population-based cohort study. PLoS One. 2021 Jul 12;16(7):e0254523. doi:
 518 10.1371/journal.pone.0254523. PMID: 34252157; PMCID: PMC8274847.
- 519 26. Davies, N., Klepac, P., Liu, Y., Prem, K., Jit, M., & Pearson, C. et al. (2020). Age520 dependent effects in the transmission and control of COVID-19 epidemics. Nature
 521 Medicine, 26(8), 1205-1211. doi: 10.1038/s41591-020-0962-9.

- 522 27. Montenegro P, Moral I, Puy A, et al. Prevalence of Post COVID-19 Condition in Primary
 523 Care: A Cross Sectional Study. Int J Environ Res Public Health. 2022;19(3):1836.
 524 Published 2022 Feb 6. doi:10.3390/ijerph19031836
- 525 28. Iwu CJ, Iwu CD, Wiysonge CS. The occurrence of long COVID: a rapid review. Pan Afr
 526 Med J. 2021;38:65. Published 2021 Jan 20. doi:10.11604/pamj.2021.38.65.27366
- 527 29. Elnadi H, Odetokun IA, Bolarinwa O, Ahmed Z, Okechukwu O, Al-Mustapha AI (2020)
 528 Knowledge, attitude, and perceptions towards the 2019 Coronavirus Pandemic: A bi529 national survey in Africa. PLoS ONE 15(7): e0236918.
 530 <u>https://doi.org/10.1371/journal.pone.023691</u>
- 30. Odetokun, I.A., Alhaji, N.B., Akpabio, U., Abdulkareem, M.A., Bilat, G.T., Subedi, D.,
 Ghali-Mohammed, I. & Elelu, N. (2022): Knowledge, risk perception and prevention
 preparedness towards COVID-19 among a cross-section of animal health professionals in
 Nigeria. *Pan African Medical Journal*. 41(20).
- Anjorin, A.A., Odetokun, I.A., Abioye, A.I., Elnadi, H., Umoren, M.V., Damaris, B.F.,
 Eyedo, J., Umar, H.I., Nyandwi, J.B., Abdalla, M.M., Tijani, S.O., Awiagah, K.S., Idowu,
 G.A., Fabrice, S.A.N., Maisara, A.M.O., Razouqi, Y., Mhgoob, Z.E., Parker, S., Asowata,
 O.E., Adesanya, I.O., Obara, M.A., Jaumdally, S., Kitema, G.F., Okuneye, T.A.,
 Mbanzulu, K.M., Daitoni, H., Hallie, E.F., Mosbah, R. & Fasina, F.O. (2021): Will
 Africans take COVID-19 vaccination? *PLoS ONE*. 16(12); e0260575.
- 541 32. Venkatesan, P. (2022). Do vaccines protect from long COVID?. The Lancet Respiratory
 542 Medicine, 10(3), e30. doi: 10.1016/s2213-2600(22)00020-0

543 33. Sheraton M, Deo N, Dutt T, Surani S, Hall-Flavin D, Kashyap R. Psychological effects of
544 the COVID 19 pandemic on healthcare workers globally: A systematic review. Psychiatry
545 research. 2020 Oct 1;292:113360.

- 546 34. Spoorthy MS, Pratapa SK, Mahant S. Mental health problems faced by healthcare workers
 547 due to the COVID-19 pandemic–A review. Asian journal of psychiatry. 2020 Jun
 548 1;51:102119.
- 549 35. Tan BY, Chew NW, Lee GK, Jing M, Goh Y, Yeo LL, Zhang K, Chin HK, Ahmad A,
 550 Khan FA, Shanmugam GN. Psychological impact of the COVID-19 pandemic on health
 551 care workers in Singapore. Annals of internal medicine. 2020 Aug 18;173(4):317-20.
- 36. Temsah MH, Al-Sohime F, Alamro N, Al-Eyadhy A, Al-Hasan K, Jamal A, Al-Maglouth
 I, Aljamaan F, Al Amri M, Barry M, Al-Subaie S. The psychological impact of COVIDpandemic on health care workers in a MERS-CoV endemic country. Journal of
 infection and public health. 2020 Jun 1;13(6):877-82.
- 37. Vizheh M, Qorbani M, Arzaghi SM, Muhidin S, Javanmard Z, Esmaeili M. The mental
 health of healthcare workers in the COVID-19 pandemic: A systematic review. Journal of
 Diabetes & Metabolic Disorders. 2020 Dec;19(2):1967-78.

- 38. Yan L, Sun P, Wang M, Song T, Wu Y, Luo J, Chen L. The psychological impact of
 COVID-19 pandemic on health care workers: a systematic review and meta-analysis.
 Frontiers in psychology. 2021;12:2382.
- 39. Chersich MF, Gray G, Fairlie L, et al. COVID-19 in Africa: care and protection for
 frontline healthcare workers. Global Health. 2020;16(1):46. Published 2020 May 15.
 doi:10.1186/s12992-020-00574-3
- Jalili M, Niroomand M, Hadavand F, Zeinali K, Fotouhi A. Burnout among healthcare
 professionals during COVID-19 pandemic: a cross-sectional study. Int Arch Occup
 Environ Health. 2021;94(6):1345-1352. doi:10.1007/s00420-021-01695-x
- 568 41. Torrente M, Sousa PA, Sánchez-Ramos A, et al. To burn-out or not to burn-out: a cross569 sectional study in healthcare professionals in Spain during COVID-19 pandemic. BMJ
 570 Open. 2021;11(2):e044945. doi:10.1136/bmjopen-2020-044945
- 571 42. Salazar de Pablo G, Vaquerizo-Serrano J, Catalan A, et al. Impact of coronavirus
 572 syndromes on physical and mental health of health care workers: Systematic review and
 573 meta-analysis. J Affect Disord. 2020;275:48-57.
- Schwartz RM, McCann-Pineo M, Bellehsen M, Singh V, Malhotra P, Rasul R, Corley SS,
 Jan S, Parashar N, George S, Yacht AC, Young JQ. The Impact of Physicians' COVID-19
 Pandemic Occupational Experiences on Mental Health. J Occup Environ Med. 2022 Feb
 1;64(2):151-157. doi: 10.1097/JOM.0000000002380
- 578 44. Chew NWS, Lee GKH, Tan BYQ, et al. A multinational, multicentre study on the
 579 psychological outcomes and associated physical symptoms amongst healthcare workers
 580 during COVID-19 outbreak. Brain Behav Immun. 2020;88:559-565.
 581 doi:10.1016/j.bbi.2020.04.049
- 582 45. Davis, H., Assaf, G., McCorkell, L., Wei, H., Low, R., & Re'em, Y. et al. (2021).
 583 Characterizing long COVID in an international cohort: 7 months of symptoms and their
 584 impact. Eclinicalmedicine, 38, 101019. doi: 10.1016/j.eclinm.2021.101019
- 585 46. Twycross A. Living with long Covid: some reflections 14 months down the line. Evid
 586 Based Nurs. 2021 May 26:ebnurs-2021-103449. doi: 10.1136/ebnurs-2021-103449
- 47. Loewenson R. COVID-19 in East and Southern Africa: Rebuilding Differently and Better
 Must Start Now. MEDICC Rev. 2020 Jul;22(3):59-60. doi:
 10.37757/MR2020.V22.N3.13.
- 48. Mendelson M, Nel J, Blumberg L, Madhi SA, Dryden M, Stevens W, Venter FWD. LongCOVID: An evolving problem with an extensive impact. S Afr Med J. 2020 Nov
 23;111(1):10-12. doi: 10.7196/SAMJ.2020.v111i11.15433.
- 49. Randremanana R, Lazoumar RH, Tejiokem MC, et al. Institut Pasteur International
 Network's efforts to guide control measures against the coronavirus disease 2019 (COVID-

- 595 19) epidemic among healthcare workers in Africa. Int J Infect Dis. 2021;103:525-526.
 596 doi:10.1016/j.ijid.2020.12.032
- 50. van Kessel SAM, Olde Hartman TC, Lucassen PLBJ, van Jaarsveld CHM. Post-acute and
 long-COVID-19 symptoms in patients with mild diseases: a systematic review. Fam Pract.
 2022;39(1):159-167. doi:10.1093/fampra/cmab076
- 51. Hopman J, Allegranzi B, Mehtar S. Managing COVID-19 in Low- and Middle-Income
 Countries. JAMA. 2020;323(16):1549–1550. doi:10.1001/jama.2020.4169.
- 52. Lam MH. Mental morbidities and chronic fatigue in severe acute respiratory syndrome
 survivors: long-term follow-up. Arch Intern Med. 2009;169(22):2142–2147
- 53. Ngai JC, Ko FW, Ng SS, et al. . The long-term impact of severe acute respiratory syndrome
 on pulmonary function, exercise capacity and health status. Respirology. 2010;15(3):543–
 550.
- 54. Aiash H, Khodor M, Shah J, et al. Integrated multidisciplinary post-COVID-19 care in
 Egypt [published correction appears in Lancet Glob Health. 2021 Jul;9(7):e915]. Lancet
 Glob Health. 2021;9(7):e908-e909. doi:10.1016/S2214-109X(21)00206-0
- 55. WHO. Keep health workers safe to keep patients safe: WHO [Internet]. Who.int. 2020 [cited
 20 September 2022]. Available from: <u>https://www.who.int/news/item/17-09-2020-keep-</u>
 health-workers-safe-to-keep-patients-safe-who
- 613

614 Legend

- Table S1. COVID-19 vaccination status in the four African countries as of 6th March 2022.
- Table S2. Association between the nationality of HCWs and their COVID-19 positivity,
- 617 vaccination rate, and awareness of PCC.
- 618